Tailored Breast Cancer Screening May Outperform Annual Mammograms

A recent study suggests that customizing breast cancer screening based on a woman’s specific risks might be more effective than traditional annual mammograms.

The research indicates that women participating in risk-based screening detected their breast cancers at earlier, more treatable stages compared to those who underwent standard annual screenings without considering personal risk factors. These findings were published in the Journal of the American Medical Association.

Dr. Laura Esserman, director of the University of California-San Francisco Breast Care Center, expressed that “these findings should transform clinical guidelines for breast cancer screening and alter clinical practice.”

In the study, over 14,000 women were screened based on their risk factors, which included age, genetics, lifestyle, health history, and breast density:

• 26% were categorized as low risk and advised to begin screenings at age 50.
• 62% were viewed as average risk and recommended to screen every two years.
• 8% had elevated risk and were suggested to screen annually.
• 2% had the highest risk and were advised to get two screenings a year, alternating between mammograms and MRIs.

Esserman explained that “the personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies.”

When comparing the outcomes of women undergoing risk-based screening with another group of over 14,000 who received annual mammograms, the results indicated fewer diagnoses of advanced cancers—specifically stage IIB or higher—among those with personalized screening.

Specifically, risk-based screening showed about 30 cases of advanced cancer per 100,000 person-years, in contrast to 48 cases per 100,000 person-years in the standard mammogram group. It’s worth noting that person-years measure the time each participant spent in the study.

The researchers highlighted that risk-based screening could uncover hidden risks; for instance, 30% of women with genetic markers that elevate their breast cancer risk did not have a family history of the disease. According to current guidelines, these women might not typically receive genetic testing.

Allison Fiscalini, director of the Athena Breast Health Network at UCSF, pointed out that “this is one of the first studies to offer genetic testing to all women, regardless of family history.” She added that when part of a comprehensive risk assessment, these insights could really enhance the safety and efficacy of screening and prevention.

Looking ahead, researchers are actively recruiting participants for a follow-up clinical trial aimed at better identifying women at greater risk for more aggressive breast cancers.

In response to the findings, the American College of Radiology cautioned that the study may not provide sufficient evidence to alter existing breast cancer screening guidelines. They noted that many women did not adhere to the recommended screening patterns, and the detected cancer rates were too low for rigorous statistical analysis.

The ACR stated, “The number of cancers found is small—likely not representative of the population,” emphasizing that less than 300 individuals were in the highest risk category.

For more information on breast cancer screening, you can consult the U.S. Centers for Disease Control and Prevention.